1. Home
  2. NAMS vs SFNC Comparison

NAMS vs SFNC Comparison

Compare NAMS & SFNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • SFNC
  • Stock Information
  • Founded
  • NAMS 2019
  • SFNC 1903
  • Country
  • NAMS Netherlands
  • SFNC United States
  • Employees
  • NAMS N/A
  • SFNC 2946
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • SFNC Major Banks
  • Sector
  • NAMS Health Care
  • SFNC Finance
  • Exchange
  • NAMS Nasdaq
  • SFNC Nasdaq
  • Market Cap
  • NAMS 3.1B
  • SFNC 2.6B
  • IPO Year
  • NAMS N/A
  • SFNC N/A
  • Fundamental
  • Price
  • NAMS $35.94
  • SFNC $17.28
  • Analyst Decision
  • NAMS Strong Buy
  • SFNC Hold
  • Analyst Count
  • NAMS 10
  • SFNC 3
  • Target Price
  • NAMS $43.70
  • SFNC $23.00
  • AVG Volume (30 Days)
  • NAMS 1.3M
  • SFNC 1.2M
  • Earning Date
  • NAMS 11-06-2025
  • SFNC 10-16-2025
  • Dividend Yield
  • NAMS N/A
  • SFNC 4.92%
  • EPS Growth
  • NAMS N/A
  • SFNC N/A
  • EPS
  • NAMS N/A
  • SFNC N/A
  • Revenue
  • NAMS $64,006,000.00
  • SFNC N/A
  • Revenue This Year
  • NAMS N/A
  • SFNC $26.06
  • Revenue Next Year
  • NAMS N/A
  • SFNC $7.70
  • P/E Ratio
  • NAMS N/A
  • SFNC N/A
  • Revenue Growth
  • NAMS 762.15
  • SFNC N/A
  • 52 Week Low
  • NAMS $14.06
  • SFNC $17.20
  • 52 Week High
  • NAMS $41.47
  • SFNC $25.95
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 59.08
  • SFNC 30.86
  • Support Level
  • NAMS $35.50
  • SFNC $17.47
  • Resistance Level
  • NAMS $36.81
  • SFNC $18.08
  • Average True Range (ATR)
  • NAMS 2.26
  • SFNC 0.56
  • MACD
  • NAMS -0.42
  • SFNC -0.07
  • Stochastic Oscillator
  • NAMS 22.49
  • SFNC 2.92

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.

Share on Social Networks: